HUE034641T2 - Eljárás túlevés vagy kényszeres evés csökkentésére - Google Patents
Eljárás túlevés vagy kényszeres evés csökkentésére Download PDFInfo
- Publication number
- HUE034641T2 HUE034641T2 HUE11844637A HUE11844637A HUE034641T2 HU E034641 T2 HUE034641 T2 HU E034641T2 HU E11844637 A HUE11844637 A HU E11844637A HU E11844637 A HUE11844637 A HU E11844637A HU E034641 T2 HUE034641 T2 HU E034641T2
- Authority
- HU
- Hungary
- Prior art keywords
- eating
- binge
- patient
- treatment
- naltrexone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (8)
- S aa bábái !>' Ί ;gèny pan · i k I. Betpropumí vágy gyógyssín-srellks: eilbgadhaSO sóját -S mtkrexoth vagy gyngysveréxáelSlsg pífög&dháíé :>'> :¾ · äS; tá ΙηΧΟί? g) OyVsXiXpS/:.': ; ipiijvds VSgV kids) SXSiXX: CVby :·. ί C ·'Cl;:·:.·!': VSU's Idkaímáááxra. ;2 övégyvseí-éssep kgsBirnersy alksimaBlsm a:·; 1, Igénypont «scsinî.. amely mapóím Kígilíljá tóválihá g beteg tááslSásál a gyógyssaobiag hatásos mennyiség napi elkalnmsapra,
- 3, Gvogysgeresnets késaitmény slkamnsassta nr 1-2 igénypontok básmciy|t.v \.·«;-;:ν. ahol a óetóg testtömeg mdexe óágyöbb vágy egyerdé? 25 kgim.
- 4, Cívógysrerés/eö késaímtóny alkalmazásra a.··: i-l, mén;. pan:ok bármelyike szerlm, ahoi a beteg nem szenved major dapressziv zavarhat;.
- 5, Gyógyszerészeti kestbonény aikBmazáxrs ay 0-~0 igénypontok b-tóme t; lka szériao amely magában foglalja to.vábbá amtak azmmsitáséó hogy a beteg major Oepn srzn /a varOrv sava vad. b. Gyógyszerészeit késyíOabay eiknio'oiaásra sa :0 igénypont avaria· ante a beteg nem szenved bipoláris zavarban.
- 7. Gyógyszerészen készimmn. níkshraxasm O-ó. Igéstypomok mo-mmy óm szetpnt. xhol á -untre von vagy gyógyszerészeti log oiOvmdháto sójának a a rapiamn hasisas sós an y i sign 4 ab mg nap ás n óoproplon vagy gyógy sáeréxzetijsg. elíogsdható sójának terápiás»!· mmemt mcsmylsége in? - HCk) mg 'nap. b. Gyógyszerészeti készítmény alkalmazásra sa 0-7. Igénypontok báraíelylke szériát. ahol a beteg nőnem-Ο7. Gyógyszerészeti készítmény aiieskvittzásrá óz S-H Sgpayposaok bárnieiyiko szériák shoS s iötóvés vagy s kényszeres evés mnmé- vagy .mértékét. tópíább s szó saie k ksi esókkesnósk,
- 10. Gyógyszerészeti ké\zi;mény mOatmszasra a 7. leenypoüi soaring sbol a csökkentett nmet vagy mérték ä lóievaxes vagy a kényszeres evesex események ézbssóge. 10 Gyögyszevészeíi kesziíníéay slkaimszásm a 7. igénypom szerint, ahol a csökkenten dinét vagy mérték a -ótóveses vagy a kényszeres evése?: események gyakoriság«.
- 12. Gyógyszetótózeti készitrnény alkalnmzasra as :0--11. igénypontok bármelyike szerint. ásni a beteg mSevését vagy kényszeres evését a kezelés megkezdése sión. és le y a OS óh vgyszo·' a kezelés megkezdésé sum íbtóvési skála (B;nge Ontmg Svától alkslmszásával mének. Ok Gyógysáni-ósaaí! készitmény slk;tim«zàsrs a 12. igénypom spring shed s kese lev megkezdésé előtti tákvesi skála érték a késelést követbe a tógalsbO lO-zai csikken vagy a kezelést követően legalább 17-re csökken.
- 01. Gyógyszerészeti \η.·ό·;;'η> alkalmazásra a··- 0-110. Igény;nmn:k Parme;;, lin. -aei-írm aim; a betege; SüevésS skála kérdőív aiPrthtnt/assysi a/mmnum udevésev zavartól vagy kénysacrcv iveses gav&i'íói sácnvédö vsïgy exek állal vesaályeatetód betegkéiit. 123703 TÉPS-iO s S. Gy4gys,a:resvot; kéasitnsé'sy aiksktn-zásra az 1-:4, Igèsyponiok bármelyike vsennt, amely zugában ‘oglaija továbbá • ùk:vksk): vagy kényszeres evestől szenvedd vagy szd: állal veszélyozieieit beteg azonosítását egy tnlevésl skála kéKÍbiv ;bkakr:a/a:.avai. nmd a beleg lestibmeg indexe ; BMI ; nagyobb vagy çgyeait) 47 kgims es a betegnek 16 mg. nyújtón halöBnyagbeadású oakrevon tg; 16Q eng nyújtott hat ban yág-i esdás á hapsmplon adagolását naponta kétszer. ·4 keinél hosszabb kezelési pmmdasban.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41935410P | 2010-12-03 | 2010-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE034641T2 true HUE034641T2 (hu) | 2018-02-28 |
Family
ID=46172302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11844637A HUE034641T2 (hu) | 2010-12-03 | 2011-12-02 | Eljárás túlevés vagy kényszeres evés csökkentésére |
Country Status (26)
Country | Link |
---|---|
US (2) | US20130252995A1 (hu) |
EP (1) | EP2646011B1 (hu) |
JP (1) | JP2014508717A (hu) |
KR (1) | KR20140035319A (hu) |
CN (1) | CN103298462A (hu) |
AR (2) | AR084093A1 (hu) |
AU (3) | AU2011336298B2 (hu) |
BR (1) | BR112013015957B1 (hu) |
CA (1) | CA2819003A1 (hu) |
CL (1) | CL2013001565A1 (hu) |
CY (1) | CY1119560T1 (hu) |
DK (1) | DK2646011T3 (hu) |
ES (1) | ES2647232T3 (hu) |
HR (1) | HRP20171678T1 (hu) |
HU (1) | HUE034641T2 (hu) |
IL (1) | IL226483A0 (hu) |
LT (1) | LT2646011T (hu) |
MX (1) | MX350304B (hu) |
NO (1) | NO2646011T3 (hu) |
PL (1) | PL2646011T3 (hu) |
PT (1) | PT2646011T (hu) |
RS (1) | RS56548B1 (hu) |
RU (1) | RU2620913C2 (hu) |
SI (1) | SI2646011T1 (hu) |
TW (2) | TWI536986B (hu) |
WO (1) | WO2012075453A1 (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
DK2135603T3 (da) | 2005-11-22 | 2013-03-25 | Orexigen Therapeutics Inc | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2197250C2 (ru) * | 2000-10-30 | 2003-01-27 | Соколовский Сергей Ростиславович | Способ лечения наркоманий |
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
CN101588795A (zh) | 2006-11-09 | 2009-11-25 | 奥雷西根治疗公司 | 包含中间快速溶解层的分层药物制剂 |
GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
WO2009035473A2 (en) * | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
WO2009080691A2 (en) * | 2007-12-20 | 2009-07-02 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound |
US20120115849A1 (en) * | 2010-11-08 | 2012-05-10 | Demopulos Gregory A | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
-
2011
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/hu unknown
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en active Application Filing
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Application Discontinuation
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
-
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
-
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
-
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
-
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017202793B2 (en) | Methods for Reducing Binge or Compulsive Eating | |
US10403170B2 (en) | Methods of treating overweight and obesity | |
CN102724878A (zh) | 在重度抑郁症患者中提供体重减轻疗法的方法 | |
Wakabayashi et al. | Diagnostic reasoning in rehabilitation nutrition: Position paper by the Japanese Association of Rehabilitation Nutrition (secondary publication) | |
Preston et al. | Medical and Psychosocial Considerations in Older Adults | |
Garrett | Perimenopause: The Savvy Sister's Guide to Hormone Harmony | |
Oparil | A 42-year-old man with hypertension | |
Bruehl et al. | Trait anger and blood pressure recovery following acute pain: evidence for opioid-mediated effects | |
Hirsch et al. | Comprehensive Geriatric Assessment | |
Kaulwar | A Meta-Analysis of various Medical Condition with Usability evaluation of Human Health Research Web Based Portal Study involving 500 Participants Data Analysis of Medical Condition | |
Woo | Nutrition in the elderly | |
Monjoghtapeh et al. | Principles Of Treatment Staff Care For Patients With Diabetes, Chronic Abdominal Pain And Hypertention In ICU Based On Pharmacology And Radiological Points: A Systematic Review | |
Saxena et al. | in obesity 39 | |
McLaren | Eating disabilities following stroke | |
Eguchi et al. | S-24-3: CURRENT TREND OF HYPERTENSION PRACTICE BY SPECIALISTS AND NON-SPECIALISTS IN THE JAPANESE PRIMARY CARE SETTINGS-J-DOME STUDY | |
Swaraj | Toxic waist: practical interventions for metabolic syndrome | |
Kouris-Blazos | Disordered eating and eating disorders | |
Roller et al. | Disease state management: Parkinson's disease | |
Jayasiri et al. | A Comparative Clinical Study on the Efficacy of Navaka Guggulu and Amritadya Guggulu in the Management of Sthaulya (Overweight and Obesity) | |
RU2788450C2 (ru) | Способы проведения терапии потери веса у пациентов с доминирующей депрессией | |
Van der Westhuizen | Obesity: evidence-based pharmacy practice | |
Khosravi et al. | Causes of failure to control hypertension in people over 65 years of age | |
Bavuma | The Effect of a Homeopathic Complex (Amylenum nitrosum 6ch, Crataegus oxyacantha 6ch, Natrum muriaticum 6ch and Scutellaria lateriflora 6ch) on Blood Pressure in Adults with Refractory Hypertension | |
SWARAJ | Toxic waist | |
Young | Meal patterns of seniors with cognitive impairment |